After seeing strength earlier, biotech stocks came under pressure in the past week. With the earnings season tapering and not much noise on the coronavirus front, the sector reacted to clinical readouts, M&A announcements, and adverse FDA rulings.

Given the current scenario, here are five defensive stocks that can return well on investment.